Cancer-Associated Venous Thromboembolism in the Real World　― From the COMMAND VTE Registry ―

Abstract

incidence compared with patients without cancer. VTE is reported to be the second most frequent cause of death in patients with cancer undergoing chemotherapy. 4 Furthermore, VTE in patients with cancer could develop through not only hypercoagulability with cancer, but also treatmentrelated factors including new molecular target therapeutic agents, which have further increased the risk for development of VTE in the current era. 5 A recent study reported Cancer is a progressive disease with a high mortality rate despite intensive treatment, but many cancer patients are surviving longer because of progress in early diagnosis and treatment. 1,2 Thus, complications during the treatment course of cancer are becoming more clinically relevant. Cancer is a strong risk factor for the development of venous thromboembolism (VTE), and patients with cancer are reported to have a 7-fold higher

Safety and Effectiveness of Apixaban in Japanese Patients With Venous Thromboembolism in Clinical Practice ― A Post-Marketing Surveillance ―

“…in Japan between 2010 and 2014, reported significantly higher cumulative 5-year incidence of major bleeding and recurrent VTE in patients with active cancer compared with those with a history of cancer or without cancer (major bleeding: 26.6%, recurrent VTE: 17.7%). 17 On the other hand, when comparing patients with active cancer, the COMMAND VTE Registry (88% of patients used warfarin) showed a higher incidence of major bleeding than the current study (cumulative 1-year incidence, 15.3% vs. 11.7%; Supplementary Figure). Although cancer types were similar between the 2 studies, this difference might be associated with the severity of patients' condition and recruitment of patients with acute symptomatic VTE, and metastatic or terminal cancer in the COMMAND VTE Registry.…”

Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction

“…The incidence of venous thromboembolism (VTE) tends to increase year by year in cancer patients but not in noncancer patients [68]. Cancer is a major risk factor for VTE, and patients with cancer account for 23-27% of patients with VTE [69,70]. Among the types of cancer, the incidence of VTE is higher in gynecologic or hematopoietic malignancies relative to the prevalence of these malignancies [70].…”

“…Cancer is a major risk factor for VTE, and patients with cancer account for 23-27% of patients with VTE [69,70]. Among the types of cancer, the incidence of VTE is higher in gynecologic or hematopoietic malignancies relative to the prevalence of these malignancies [70]. Patients with cancer often suffer from recurrent VTE or major bleeding due to difficulties with anticoagulation control.…”

“…Patients with cancer often suffer from recurrent VTE or major bleeding due to difficulties with anticoagulation control. VTE is also more likely to develop in patients with cancer during chemotherapy and those with distant metastases [70]. Therefore, patients with cancer should be treated with awareness of the high risk of VTE according to cancer sites and cancer status.…”

Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?

“…Recently, the COMMAND VTE (COntemporary ManageMent AND outcomes in patients with Venous ThromboEmbolism) Registry assessed clinical characteristics, management strategies, and outcomes in patients with acute symptomatic VTE in real-life [30]. This multicentric registry enrolled 3027 consecutive patients with acute symptomatic VTE in Japan between 2010 and 2014.…”